Step-up Therapy in Persistent Asthma
A 33-year-old woman with bronchial asthma and chronic rhinosinusitis reports worsening breathlessness and a cough that wakes her three nights per week. She uses her salbutamol inhaler about five times per week during the day. Oxygen saturation is 97% on room air, with bilateral expiratory wheezes. Spirometry shows an FEV1 of 74% predicted that improves by 14% after bronchodilator. Which of the following should be added to her management plan?
- A.Oral prednisone
- B.Oral montelukast
- C.Inhaled budesonideCorrect
- D.Inhaled ipratropium bromide
Explanation
She has uncontrolled asthma on short-acting beta-2 agonist alone, with night waking three times a week, daytime reliever use more than twice weekly, and reduced lung function. The single most important step is to introduce an inhaled corticosteroid, which is the only class that treats the underlying eosinophilic airway inflammation and the only one shown to reduce asthma exacerbations and asthma death. GINA explicitly advises against short-acting beta-2 agonist only treatment at any step because relying on a bronchodilator alone leaves inflammation untreated and is associated with increased mortality; current preferred therapy is a low dose inhaled corticosteroid plus formoterol used as needed or as maintenance and reliever therapy. Montelukast is a less effective controller, is reserved as an add-on or alternative particularly with concomitant allergic rhinitis or aspirin exacerbated respiratory disease, and now carries a boxed warning for neuropsychiatric events. Oral prednisone treats acute exacerbations and severe refractory disease, but this woman is not in an acute exacerbation and chronic systemic steroids cause osteoporosis, adrenal suppression, hyperglycaemia, and cataracts. Ipratropium is a short-acting muscarinic antagonist with a role in acute severe asthma and in COPD, not as a chronic controller in asthma. Her rhinosinusitis is worth noting because upper airway inflammation frequently drives poor asthma control, and the combination of asthma, nasal polyps, and aspirin sensitivity constitutes Samter triad. Inhaler technique and adherence must be checked before any step-up in therapy.
Why each option
- A.
- Systemic steroids are for acute exacerbations or severe refractory disease, not for first-line chronic control in moderate asthma.
- B.
- Montelukast is a weaker controller used as an alternative or add-on, and carries a boxed warning for neuropsychiatric adverse effects.
- C.
- Correct. Inhaled corticosteroid is the foundational controller for persistent asthma and is the only class that reduces exacerbations and asthma death.
- D.
- Ipratropium is useful in acute severe asthma and in COPD but is not a maintenance controller for asthma.
Reference: GINA Global Strategy for Asthma Management and Prevention, 2024
This is one of 3,306 questions in the MedBoardSA SMLE bank, with timed test mode, tutor mode, and progress tracking by topic.
Practise the full bank